A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety,Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety,Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs AK 002 (Primary)
  • Indications Eosinophilic gastroenteritis
  • Focus Therapeutic Use
  • Acronyms ENIGMA
  • Sponsors Allakos
  • Most Recent Events

    • 08 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 08 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
    • 16 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top